https://businesscurrentsdenmark.com/article/909080187-zealand-pharma-and-roche-to-advance-petrelintide-an-amylin-analog-to-phase-3-trials-for-chronic-weight-management Business Currents Denmark en PressRelease 2026-04-29T17:01:00+00:00 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png https://businesscurrentsdenmark.com/article/908371450-jaecoo-7-shs-h-completes-nine-country-super-hybrid-marathon-test-presented-at-ibs-and-auto-show Business Currents Denmark en PressRelease 2026-04-28T05:22:21+00:00 JAECOO 7 SHS-H Completes Nine-Country Super Hybrid Marathon Test; Presented at IBS and Auto Show https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24841283-21313-1600x900.jpeg https://businesscurrentsdenmark.com/article/908661479-zealand-pharma-announces-boehringer-ingelheim-s-novel-glucagon-glp-1-dual-agonist-survodutide-achieved-significant-weight-loss-of-16-6-delivering Business Currents Denmark en PressRelease 2026-04-28T06:00:00+00:00 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png